Fishman Jay A Ltd. MI Decreases Stake in Pfizer Inc. (NYSE:PFE)

Fishman Jay A Ltd. MI lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 282,174 shares of the biopharmaceutical company’s stock after selling 7,630 shares during the quarter. Pfizer comprises about 0.8% of Fishman Jay A Ltd. MI’s holdings, making the stock its 23rd largest holding. Fishman Jay A Ltd. MI’s holdings in Pfizer were worth $7,150,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Pfizer by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after acquiring an additional 2,285,276 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Geode Capital Management LLC boosted its stake in Pfizer by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after buying an additional 2,923,537 shares in the last quarter. Norges Bank bought a new position in Pfizer during the fourth quarter valued at about $2,328,986,000. Finally, Massachusetts Financial Services Co. MA raised its holdings in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on PFE shares. Cantor Fitzgerald started coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Trading Up 0.4%

PFE stock opened at $23.97 on Friday. The company has a market cap of $136.27 billion, a P/E ratio of 17.37, a PEG ratio of 0.87 and a beta of 0.57. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The business has a fifty day moving average of $23.26 and a 200-day moving average of $24.90.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the company posted $0.82 earnings per share. The firm’s revenue was down 7.8% on a year-over-year basis. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.18%. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.